Application Detail
Description of Medical Service
Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T (CAR-T) cell therapy for treatment of patients with multiple myeloma (MM) who are refractory or have failed more than three lines of prior therapy. The therapy involves taking the patient’s own cells from peripheral blood, enriching them for T-cells (a type of white blood cell that is an essential part of the immune system) and genetically modifying them before infusing them back into the patient to treat the MM.Description of Medical Condition
Multiple Myeloma (MM) is a cancer affecting a type of white blood cell, known as a plasma cell. Plasma cells are found in the bone marrow and make up a part of the immune system. When cancerous, they accumulate to a point where there is not enough space left for normal, healthy blood cells to be produced. MM can cause bone disease, kidney problems, anaemia, increased risk of infection and blood-clotting.Reason for Application
Highly Specialised Therapy- National Health Reform AgreementMedical Service Type
Therapeutic technologyPrevious Application Number/s
1690Associated Documentation
PICO Set
PICO Set (PDF 881 KB)PICO Set (Word 136 KB)
Consultation Survey
Consultation Survey (PDF 658 KB)Consultation Survey (Word 27 KB)
PASC Consultation
Expedited – Bypassing PASC
MSAC Consultation
MSAC consultation input closed.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process
PICO Confirmation
-Assessment Report
-Public Summary Document
Public Summary Document - November 2023 (PDF 999 KB)Public Summary Document - November 2023 (Word 219 KB)
Public Summary Document - April 2024 (PDF 326 KB)
Public Summary Document - April 2024 (Word 113 KB)
Meetings for this Application
PASC
Expedited – Bypassing PASCESC
5-6 October 2023MSAC
23-24 November 20234-5 April 2024